FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthias Ritgen

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Genes & Molecular Sequences

Genes, Immunoglobulin

Anatomy

Chromosomes, Human, Pair 14

Co-author Network

Publications

TOP 3
Peter Dreger; Michael Hallek; Ute Hegenbart; Michael Kneba; Peter Paschka; Matthias Ritgen; Marianna Rossi; Christof Scheid; Norbert Schmitz; Andrea Schnaiter; Michael Stadler; Sebastian Böttcher; Andreas Bühler; Donald Bunjes; Raymonde Busch; Sascha Dietrich; Hartmut Döhner; Lutz Uharek; Matthias Zeis; Thorsten Zenz; Stephan Stilgenbauer
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Sebastian Böttcher; Michael Hallek; Matthias Ritgen; Michael Kneba
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?
Thorsten Raff; Regina Reutzel; Matthias Ritgen; H Trautmann; Nicola Gökbuget; Dieter Hoelzer; M Kaiser; Michael Kneba; Silke Lüschen; Monika Brüggemann
Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthias Ritgen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter Dreger; Michael Hallek; Ute Hegenbart; Michael Kneba; Peter Paschka; Matthias Ritgen; Marianna Rossi; Christof Scheid; Norbert Schmitz; Andrea Schnaiter; Michael Stadler; Sebastian Böttcher; Andreas Bühler; Donald Bunjes; Raymonde Busch; Sascha Dietrich; Hartmut Döhner; Lutz Uharek; Matthias Zeis; Thorsten Zenz; Stephan Stilgenbauer
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Blood 2013;121(16):3284-8.
2013: Sebastian Böttcher; Michael Hallek; Matthias Ritgen; Michael Kneba
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?
Hematology/oncology clinics of North America 2013;27(2):267-88.
2013: Thorsten Raff; Regina Reutzel; Matthias Ritgen; H Trautmann; Nicola Gökbuget; Dieter Hoelzer; M Kaiser; Michael Kneba; Silke Lüschen; Monika Brüggemann
Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease.
Leukemia 2013;27(4):989-92.
2013: V Goede; G Bieska; R Busch; S De Guibert; M-S Dilhuydy; A Engelke; K Fischer; K Humphrey; U Jaeger; A W Langerak; Matthias Ritgen; M Wenger; N Wickham; Michael Hallek
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.
Leukemia 2013;27(5):1172-4.
2013: Christiane Pott; Matthias Ritgen; Vincent H J van der Velden; Jacques J M van Dongen; Monika Brüggemann; Michael Kneba
MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Methods in molecular biology (Clifton, N.J.) 2013;971():175-200.
2013: Sebastian Böttcher; Matthias Ritgen; Michael Kneba
Flow cytometric MRD detection in selected mature B-cell malignancies.
Methods in molecular biology (Clifton, N.J.) 2013;971():149-74.
2013: A C Rawstron; Matthias Ritgen; J Shingles; N Villamor; Sebastian Böttcher; F Cymbalista; Ruth de Tute; C Fazi; Paolo Ghia; M Hallek; P Hillmen; H Kartsios; Michael Kneba; Rémi Letestu; K Lin; E Montserrat; C Moreno; A R Pettitt
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Leukemia 2013;27(1):142-9.
2012: Thomas Elter; Andreas Engert; A-M Fink; K Fischer; W Gassmann; J Bahlo; Sebastian Böttcher; Andreas Bühler; R Busch; Hartmut Döhner; I Hasan; R James; C Kahl; Matthias Ritgen; Peter Staib; M Stauch; Stephan Stilgenbauer; Clemens-Martin Wendtner; Dirk Winkler; Michael Hallek
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
Leukemia 2012;26(12):2549-52.
2012: Kirsten Fischer; Valentin Goede; Michael Hallek; Susanne Isfort; Michael Kneba; Karl-Anton Kreuzer; Karl H Pflüger; Matthias Ritgen; Silke Schott; Jöerg Schubert; Peter Staib; Stephan Stilgenbauer; Julia von Tresckow; Jasmin Bahlo; Sebastian Böttcher; Andreas Bühler; Raymonde Busch; Paula Cramer; Hartmut Döhner; Barbara F Eichhorst; Anna-Maria Fink; Dirk Winkler; Clemens-Martin Wendtner
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(26):3209-16.
2012: Tomas Kalina; L Lhermitte; M Martin-Ayuso; Ester Mejstrikova; A Mendonça; Alberto Orfao; José J Pérez; Matthias Ritgen; L Sedek; T Szczepański; Jeroen te Marvelde; V H J van der Velden; J J M van Dongen; María-Belén Vidriales; Julia Almeida; Vahid Asnafi; Sebastian Böttcher; M Cullen; R de Tute; J Flores-Montero; Ondrej Hrusak
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.
Leukemia 2012;26(9):1986-2010.
2012: Peter Dreger; Ulrich Dührsen; Anna-Maria Fink; Hildegard Greinix; Michael Hallek; Manfred Hensel; Wolfgang Knauf; Michael Kneba; Fabienne McClanahan; Michael Pfreundschuh; Matthias Ritgen; Johannes Schetelig; Norbert Schmitz; Michael Stadler; Stephan Stilgenbauer; Dirk Winkler; Günter Brittinger; Andreas Bühler; Raymonde Busch; Hartmut Döhner
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Blood 2012;119(21):4851-9.
2012: Sebastian Böttcher; Andreas Bühler; Raymonde M Busch; Hartmut Döhner; Barbara F Eichhorst; G Fingerle-Rowson; Anna Maria Fink; Kirsten Fischer; Michael J Hallek; Myriam Mendila; Matthias Ritgen; Stephan Stilgenbauer; Clemens-Martin Wendtner; Michael Karl Wenger; Thorsten Zenz; Michael Kneba
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(9):980-8.
2011: Sebastian Böttcher; Matthias Ritgen; Peter Dreger
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies.
Blood reviews 2011;25(2):91-6.
2011: Barbara F Eichhorst; Kirsten Fischer; Anna-Maria Fink; Thomas Elter; Clemens-Martin Wendtner; Valentin Goede; Manuela Bergmann; Stephan Stilgenbauer; Georg Hopfinger; Matthias Ritgen; Jasmin Bahlo; Raymonde Busch; Michael Hallek
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Blood 2011;117(6):1817-21.
2010: Peter Dreger; Hartmut Döhner; Matthias Ritgen; S Böttcher; Raymonde Busch; Sascha Dietrich; Donald Bunjes; Sandra Cohen; Jörg Schubert; Ute Hegenbart; Dietrich W Beelen; Matthias Zeis; Michael Stadler; Justin Hasenkamp; Lutz Uharek; Christof Scheid; Andreas Humpe; Thorsten Zenz; Dirk Winkler; Michael Hallek; Michael Kneba; Norbert Schmitz; Stephan Stilgenbauer
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Blood 2010;116(14):2438-47.
2010: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; Matthias Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Lancet 2010;376(9747):1164-74.
2010: Carol Moreno; Matthias Ritgen; Andy C Rawstron
Is MRD eradication a desirable goal in CLL?
Best practice & research. Clinical haematology 2010;23(1):97-107.
2009: Sebastian Böttcher; Stephan Stilgenbauer; R Busch; Monika Brüggemann; Thorsten Raff; Christiane Pott; K Fischer; G Fingerle-Rowson; Hartmut Döhner; Michael Hallek; Michael Kneba; Matthias Ritgen
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Leukemia 2009;23(11):2007-17.
2009: Barbara F Eichhorst; Raymonde Busch; Stephan Stilgenbauer; Martina Stauch; Manuela A Bergmann; Matthias Ritgen; Nicole Kranzhöfer; Robert Rohrberg; Ulrike Söling; Oswald Burkhard; Anne Westermann; Valentin Goede; Carmen Schweighofer; Kirsten Fischer; Anna-Maria Fink; Clemens-Martin Wendtner; Günter Brittinger; Hartmut Döhner; Bertold Emmerich; Michael Hallek
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Blood 2009;114(16):3382-91.
2009: Inga Nagel; Takashi Akasaka; Wolfram Klapper; Stefan Gesk; Sebastian Böttcher; Matthias Ritgen; Lana Harder; Michael Kneba; Martin J S Dyer; Reiner Siebert
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma.
Haematologica 2009;94(7):1020-3.
2009: Carmen D Schweighofer; Matthias Ritgen; Barbara F Eichhorst; Raymonde Busch; Wolfgang Abenhardt; Michael Kneba; Michael Hallek; Clemens-Martin Wendtner
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
British journal of haematology 2009;144(1):95-8.
2008: Jolanta B Perz; Matthias Ritgen; Marion Moos; Anthony Ho; Michael Kneba; Peter Dreger
Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML.
Bone marrow transplantation 2008;42(10):687-8.
2008: Matthias Ritgen; S Böttcher; S Stilgenbauer; D Bunjes; J Schubert; S Cohen; A Humpe; M Hallek; M Kneba; Norbert Schmitz; H Döhner; P Dreger
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
Leukemia 2008;22(7):1377-86.
2008: Sebastian Böttcher; Matthias Ritgen; Sebastian Buske; Stefan Gesk; Wolfram Klapper; Eva Hoster; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling; Reiner Siebert; Michael Kneba; Christiane Pott
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Haematologica 2008;93(4):551-9.
2007: Ludger Sellmann; Stefan Gesk; Christoph Walter; Matthias Ritgen; Lana Harder; José I Martín-Subero; Roland Schroers; Dörte Siemer; Holger Nückel; Martin J S Dyer; Ulrich Dührsen; Reiner Siebert; Jan Dürig; Ralf Küppers
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia.
British journal of haematology 2007;138(2):217-20.
2007: José I Martín-Subero; Rachel E Ibbotson; Wolfram Klapper; L Michaux; Evelyne Callet-Bauchu; F Berger; María J Calasanz; C De Wolf-Peeters; Martin J S Dyer; Pascale Felman; Anne Gardiner; Randy D Gascoyne; Stefan Gesk; Lana Harder; D E Horsman; Michael Kneba; Ralf Küppers; A Majid; Nilima Parry-Jones; Matthias Ritgen; M Salido; F Solé; G Thiel; Hans-Heinrich Wacker; David Oscier; Iwona Wlodarska; Reiner Siebert
A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.
Leukemia 2007;21(7):1532-44.
2007: Andy C Rawstron; N Villamor; Matthias Ritgen; Sebastian Böttcher; Paolo Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; Massimo Geuna; P A S Evans; Yasodha Natkunam; S E Coutre; E D Avery; Laura Rassenti; Thomas Kipps; Federico Caligaris-Cappio; Michael Kneba; J C Byrd; Michael Hallek; E Montserrat; Peter Hillmen
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Leukemia 2007;21(5):956-64.
2007: Thorsten Raff; Nicola Gökbuget; Silke Lüschen; Regina Reutzel; Matthias Ritgen; Sebastian Irmer; Sebastian Böttcher; Heinz-August Horst; Michael Kneba; Dieter Hoelzer; Monika Brüggemann
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.
Blood 2007;109(3):910-5.
2006: Frank Moosig; F Damm; Anja Knorr-Spahr; Matthias Ritgen; Rainald A Zeuner; M Kneba; M Ernst; Johann O Schröder
Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus.
Clinical and experimental immunology 2006;146(3):409-16.
2006: Frank Moosig; Erika Fähndrich; Anja Knorr-Spahr; Sebastian Böttcher; Matthias Ritgen; Rainald A Zeuner; Michael Kneba; Johann O Schröder
C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus.
Rheumatology international 2006;26(12):1109-12.
2006: Thorsten Zenz; Matthias Ritgen; Peter Dreger; Alexander Kröber; Thomas F E Barth; Richard F Schlenk; Sebastian Böttcher; Michael Hallek; Michael Kneba; Donald Bunjes; Hartmut Döhner; Stephan Stilgenbauer
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Blood 2006;108(6):2127-30.
2006: Rémi Letestu; Andy C Rawstron; Paolo Ghia; Neus Villamor; Nancy Boeckx; Nancy Boeckx Leuven; Sebastian Boettcher; Anne Mette Buhl; Jan Duerig; Rachel E Ibbotson; Alexander Kroeber; Anton Langerak; Magali Le Garff-Tavernier; Ian Mockridge; Alison Morilla; Ruth Padmore; Laura Rassenti; Matthias Ritgen; Medhat Shehata; Piotr Smolewski; Peter Staib; Michel Ticchioni; Clare Walker; Florence Cymbalista
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
Cytometry. Part B, Clinical cytometry 2006;70(4):309-14.
2006: Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Blood 2006;107(6):2271-8.
2006: Monika Brüggemann; Thorsten Raff; Thomas Flohr; Nicola Gökbuget; Makoto Nakao; Jo Droese; Silke Lüschen; Christiane Pott; Matthias Ritgen; Urban J Scheuring; Heinz-August Horst; Eckhard Thiel; Dieter Hoelzer; Claus R Bartram; Michael Kneba
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
Blood 2006;107(3):1116-23.
2005: Sebastian Böttcher; Matthias Ritgen; Monika Brüggemann; Thorsten Raff; Silke Lüschen; Andreas Humpe; Michael Kneba; Christiane Pott
Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.
Journal of immunological methods 2005;306(1-2):128-36.
2005: Peter Dreger; Matthias Ritgen; Sebastian Böttcher; Norbert Schmitz; Michael Kneba
The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?
Leukemia 2005;19(7):1135-8.
2005: Christiane Pott; Carsten Schrader; Monika Brüggemann; Matthias Ritgen; Lana Harder; Thorsten Raff; Markus Tiemann; Peter Dreger; Michael Kneba
Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
European journal of haematology 2005;74(4):353-8.
2004: Matthias Ritgen; Stephan Stilgenbauer; Nils von neuhoff; Andreas Humpe; Monika Brüggemann; Christiane Pott; Thorsten Raff; Alexander Kröber; Donald Bunjes; Richard F Schlenk; Norbert Schmitz; Hartmut Döhner; Michael Kneba; Peter Dreger
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
Blood 2004;104(8):2600-2.
2004: Sebastian Böttcher; Matthias Ritgen; Christiane Pott; Monika Brüggemann; Thorsten Raff; Stephan Stilgenbauer; Hartmut Döhner; Peter Dreger; Michael Kneba
Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Leukemia 2004;18(10):1637-45.
2004: Clemens-Martin Wendtner; Matthias Ritgen; Carmen Schweighofer; G Fingerle-Rowson; Hartmut Campe; Gabriele Jäger; Barbara F Eichhorst; Raymonde Busch; Heinz Diem; A Engert; Stephan Stilgenbauer; Hartmut Döhner; Michael Kneba; Bertold Emmerich; Michael Hallek
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Leukemia 2004;18(6):1093-101.
2004: Monika Brüggemann; V H J van der Velden; Thorsten Raff; Jo Droese; Matthias Ritgen; Christiane Pott; A J M Wijkhuijs; Nicola Gökbuget; Dieter Hoelzer; Elisabeth R van Wering; Jacques J M van Dongen; Michael Kneba
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Leukemia 2004;18(4):709-19.
2004: Peter Dreger; Stephan Stilgenbauer; Axel Benner; Matthias Ritgen; Alexander Kröber; Michael Kneba; Norbert Schmitz; Hartmut Döhner
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.
Blood 2004;103(7):2850-8.
2004: Monika Brüggemann; Christiane Pott; Matthias Ritgen; Michael Kneba
Significance of minimal residual disease in lymphoid malignancies.
Acta haematologica 2004;112(1-2):111-9.
2003: Matthias Ritgen; Alexandra Lange; Stephan Stilgenbauer; Hartmut Dohner; Christian Bretscher; Heidi Bosse; Ariane Stuhr; Michael Kneba; Peter Dreger
Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.
Blood 2003;101(5):2049-53.
1997: Meinolf Suttorp; Matthias Ritgen; Nils von neuhoff; Robert Schoch; Norbert Schmitz
Blood on filter paper as a readily available source of bcr-abl rearranged mRNA.
Blood 1997;90(4):1713-5.